XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenue $ 519,359 $ 486,030
Product    
Disaggregation of Revenue [Line Items]    
Revenue 505,525 467,769
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim    
Disaggregation of Revenue [Line Items]    
Revenue 481,143 417,760
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 156,832 148,872
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | United States    
Disaggregation of Revenue [Line Items]    
Revenue 150,815 155,064
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Middle East    
Disaggregation of Revenue [Line Items]    
Revenue 65,607 15,559
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America    
Disaggregation of Revenue [Line Items]    
Revenue 62,544 59,705
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world    
Disaggregation of Revenue [Line Items]    
Revenue 45,345 38,560
Marketed by Sanofi | Aldurazyme    
Disaggregation of Revenue [Line Items]    
Revenue $ 24,382 $ 50,009